Cambridge Cognition Holdings strong results and record sales intake (VIDEO)

Cambridge Cognition Holdings plc (LON:COG) CEO Matthew Stork and new CFO Stephen Symonds join DirectorsTalk Interviews to discuss preliminary results for the year ended 31st December 2021.

Stephen having joined the company only last week provides us with some background while Matthew talks us through the results highlights, record sales order intake, continued growth in the clinical trials market, the successful spin-out of digital phenotyping business Monument Therapeutics and what we can expect from the company over the next 12 months.

Cambridge Cognition Holdings (LON: COG) is a world leading neuroscience technology company committed to enhancing global research, accelerating treatment development and improving patient outcomes in conditions affecting brain health by optimising the assessment of cognition.

Find more news, interviews, share price & company profile here for:
Cambridge Cognition Holdings plc

Share this interview

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on whatsapp
WhatsApp
Cambridge Cognition Holdings strong results and record sales intake (VIDEO)

Other Interviews

More News

Ask your questions

Do you have questions you’d like to ask this company, get in touch and we’ll ask them for you.   

I have questions